The global asthma and COPD market is predicted to be worth US$ 30,710.2 million, and by 2027
More than a "smoker's cough" or a chronic cough and shortness, Chronic Obstructive Pulmonary Disease (COPD) is defined by a persistent restriction of airflow in the lungs, resulting in abnormal sputum. Cough, dyspnea (shortness of breath) and wheezing, sputum, chest infections, weight loss, weariness, and ankle swelling are all symptoms of COPD.
In 2020, the global asthma and COPD market is predicted to be worth US$ 30,710.2 million, and by 2027, it is expected to be worth US$ 42,608 million.
Global Asthma and COPD Market: Drivers
Over the forecast period, the worldwide asthma and COPD market is expected to rise due to rising COPD prevalence. According to the Global Initiative for Chronic Obstruction Disease's 2018 study, COPD is estimated to kill 4.5 million people worldwide each year by 2030.
Furthermore, the industry is predicted to rise as the number of smokers grows. According to the World Health Organization, 1.337 billion people globally smoked tobacco in 2018.
In terms of value, Combination Therapies dominated the global asthma and COPD market in 2019, accounting for 57.0 percent of the market, followed by Bronchodilators and Anti-Inflammatories.
Comments
Post a Comment